Medicine and Health

Locoregional delivery of IL-13Rx2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial

C. E. Brown, J. C. Hibbard, et al.

This groundbreaking phase I trial evaluated the effectiveness of IL-13Rx2-targeted CAR-T cells in 65 patients suffering from recurrent high-grade glioma. The study revealed that locoregional CAR-T cell administration was both feasible and well-tolerated, achieving stable disease or better in 50% of patients. Notably, median overall survival improved significantly based on treatment variations. This promising research was conducted by a team of dedicated researchers at City of Hope.